Evidence map›Paper›PMID 33849580›Full record

ArticleSubstance abuse treatment, prevention, and policy2021

Cannabis use in patients treated for opioid use disorder pre- and post-recreational cannabis legalization in Canada.

Tea Rosic, Nitika Sanger, Balpreet Panesar, Gary Foster, David C Marsh, Launette Rieb, Lehana Thabane, Andrew Worster, Zainab Samaan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tea RosicDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
Nitika SangerMedical Sciences Graduate Program, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
Balpreet PanesarNeurosciences Graduate Program, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
Gary FosterDepartment of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
David C MarshNorthern Ontario School of Medicine, 935 Ramsey Lake Rd, Sudbury, ON, P3E 2C6, Canada.
Launette RiebDepartment of Family Practice, University of British Columbia and St. Paul's Hospital, 1081 Burrard St, Hornby site, Vancouver, BC, V6Z 1Y6, Canada.
Lehana ThabaneDepartment of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
Andrew WorsterDepartment of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
Zainab SamaanDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada. samaanz@mcmaster.ca.ORCID 0000-0002-5974-9361

Funding

Canadian Institutes for Health Research PJT-156306Canadian Institutes for Health Research SHI-155404
6 · The paper itself

Abstract

backgroundAs the legalization of recreational cannabis becomes more widespread, its impact on individuals with substance use disorders must be studied. Amidst an ongoing opioid crisis, Canada's legalization of recreational cannabis in October 2018 provides an important setting for investigation. We examined changes to cannabis use patterns in patients receiving medication-assisted treatment (MAT) for opioid use disorder (OUD) following legalization.

methodsThis study includes cross-sectional data from 602 participants recruited 6 months pre-legalization and 788 participants recruited 6 months post-legalization, providing information on cannabis use. Regression analysis was used to estimate the association between legalization and cannabis use patterns. We collected longitudinal urine drug screens (UDSs) detecting cannabis-metabolites for 199 participants recruited pre-legalization and followed prospectively post-legalization. Conditional logistic regression was used to assess the association between legalization and UDS results.

resultsPast-month cannabis use was self-reported by 54.8 and 52.3% of participants recruited pre- and post-legalization, respectively. Legalization was not associated with changes in any measured cannabis characteristics: cannabis use (OR 0.91, 95% CI 0.73-1.13), days of use/month (B -0.42, 95% CI - 2.05-1.21), money spent, or cannabis source. There was no association between legalization and prevalence of cannabis use on UDS (OR 1.67, 95% CI 0.93-2.99) or percentage of cannabis-positive UDSs (OR 1.00, 95% CI 0.99-1.01). Participants overwhelmingly reported that legalization would have no impact on their cannabis use (85.7%).

conclusionsAmongst patients treated for OUD, no significant change in cannabis use was observed following legalization; however, high rates of cannabis use are noted.

Indexed as

CannabisOpioid-Related DisordersCanadaCross-Sectional StudiesHumansLegislation, DrugBuprenorphineCannabisComorbidityLegalizationMethadonePolysubstance useRecreational

Identifiers

PMID33849580
PMCPMC8045320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.